Desai Shares & Stock Pvt Ltd acquires additional 1,356 shares in Bharat Parenterals Ltd

What Bharat Parenterals Ltd announced

Bharat Parenterals Ltd (BSE script code 541096) filed a disclosure on 30 June 2026 under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing confirms that Desai Shares & Stock Pvt Ltd, a promoter‑linked entity, acquired an additional 1,356 equity shares of Bharat Parenterals Ltd on the open market.

The acquisition took place over a period spanning 1 June 2026 to 25 June 2026. After the purchase, Desai Shares & Stock Pvt Ltd’s holding rose to 2,733,792 shares, representing 39.67 % of the total diluted voting capital of the target company.

Details of the acquisition

• Acquirer: Desai Shares & Stock Pvt Ltd (DIN 05425782) – identified as belonging to the promoter group of Bharat Parenterals Ltd.
• Target: Bharat Parenterals Ltd, listed on BSE (code 541096).
• Mode of acquisition: Open‑market purchase.
• Number of shares acquired: 1,356 equity shares carrying voting rights.
• Holding before acquisition: 2,732,436 shares (39.65 % of diluted voting capital).
• Holding after acquisition: 2,733,792 shares (39.67 % of diluted voting capital).
• Date range of purchase: 1 June 2026 – 25 June 2026.
• Total equity share capital of Bharat Parenterals Ltd: 68,91,963 shares of Rs 10 each, aggregating to Rs 6.89 billion (both before and after the transaction).

The filing notes that the total diluted share/voting capital of Bharat Parenterals Ltd remains unchanged at 68,91,963 shares, as the acquisition did not involve any convertible securities, warrants, or other instruments that could alter the capital structure.

Key facts at a glance

Why this matters for investors

The disclosure satisfies SEBI’s requirement to inform the market when a promoter or promoter‑group entity makes a substantial acquisition of shares. Although the increase in stake is modest—only 0.02 percentage points—it confirms that the promoter continues to maintain a dominant shareholding (just under 40 %).

For shareholders, the key implications are:

• No dilution: The transaction did not involve issuance of new shares or conversion of securities, so existing shareholders’ proportional ownership remains unchanged.
• Transparency: The filing provides a clear record of the promoter’s buying activity, helping investors assess the promoter’s confidence in the business.
• Regulatory compliance: By filing under Regulation 29(2), the company demonstrates adherence to SEBI’s takeover code, reducing the risk of regulatory penalties.

Investors should note that the acquisition does not trigger any mandatory open‑offer requirement because the promoter’s holding remains below the 25 % threshold that would otherwise necessitate an offer to the public.

Conclusion

Desai Shares & Stock Pvt Ltd increased its promoter stake in Bharat Parenterals Ltd by 1,356 shares, taking its holding to 39.67 % of the diluted voting capital. The purchase was executed on the open market between 1 June and 25 June 2026 and was disclosed in a SEBI Regulation 29(2) filing on 30 June 2026. No change to the company’s capital structure or shareholder composition beyond the marginal increase in promoter ownership was reported.